Real-World Long-Term Efficacy of Chemoimmunotherapy in Advanced Stage Small-Cell Lung Cancer
Respiration · 02.07.2026 · 1-13
DOI: 10.1159/000553352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiration, online erschienen am 02.07.2026. Verfasst von Arne Peeters und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Diseases and Respiratory Oncology Unit, University Hospitals Leuven, Leuven, Belgium. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Introduction
Since IMpower133 and CASPIAN phase 3 trials, chemoimmunotherapy has become the first-line systemic treatment for advanced-stage small-cell lung carcinoma (SCLC). We conducted a study on the long-term efficacy.
Methods
A retrospective cohort study was performed on advanced-stage SCLC patients who initiated treatment with first-line carboplatin-etoposide-atezolizumab between January 2018 and December 2022 at the University Hospitals Leuven. Follow-up data were collected until February 2025. The Kaplan-Meier method was used for estimating survival outcomes, and Cox regression models were used to assess the association between baseline clinical characteristics (age, ECOG Performance Status, metastatic sites, s-albumin, s-lactate dehydrogenase, s-C-reactive protein, s-NSE, neutrophil-lymphocyte ratio [NLR], modified Glasgow Prognostic Score [mGPS], and Lung Immune Prognostic Index [LIPI] score) and survival outcomes.
Results
A total of 74 patients were included. The median progression-free survival (PFS) was 4.8 months (95% CI: 4.5–5.0), and median overall survival (OS) was 11.5 months (95% CI: 8.9–14.6). The 1-, 2-, and 5-year PFS and OS rates were 16.2% (95% CI: 8.9–25.5), 9.5% (95% CI: 4.2–17.4), and 8.1% (95% CI: 3.3–15.7) and 47.3% (95% CI: 35.6–58.1), 18.9% (95% CI: 11.0–28.5), and 8.9% (95% CI: 3.2–18.2%), respectively. In multivariable analysis, bone metastasis (HR 2.21; 95% CI: 1.26–3.87), age (+1 year, HR 1.03; 95% CI: 1.00–1.07), s-NSE >250 μg/L (HR 4.55; 95% CI: 2.13–9.72), and s-albumin ≥35 g/dL (HR 0.49; 95% CI: 0.25–0.99) were significantly associated with OS. During induction phase, chemotherapy dose reduction and discontinuation occurred in 31% and 8%, respectively. Overall, immune-related adverse events occurred in 21 patients (28%), leading to discontinuation of atezolizumab in 7 patients (10%).
Conclusion
Our study provides long-term safety and efficacy outcomes of first-line chemoimmunotherapy in a real-world cohort of advanced-stage SCLC. In multivariable analysis, we found that baseline conventional biomarkers (age, bone metastasis, s-albumin, and s-NSE) did significantly predict OS, while systemic inflammation scores (NLR, mGPS, and LIPI) did not.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Diseases and Respiratory Oncology Unit, University Hospitals Leuven, Leuven, Belgium.
- Department of Chronic Diseases and Metabolism Leuven, BREATHE, KU Leuven, Leuven, Belgium.
- Department of Respiratory Diseases and Respiratory Oncology Unit, University Hospitals Leuven, Leuven, Belgium, christophe.dooms@uzleuven.be.
- Department of Chronic Diseases and Metabolism Leuven, BREATHE, KU Leuven, Leuven, Belgium, christophe.dooms@uzleuven.be.
Zitieren
APA
Peeters, A., Wauters, E., Wauters, I., Van Hove, K., & Dooms, C. (2026). Real-World Long-Term Efficacy of Chemoimmunotherapy in Advanced Stage Small-Cell Lung Cancer. Respiration, 1-13. https://doi.org/10.1159/000553352
Vancouver
Peeters A, Wauters E, Wauters I, Van Hove K, Dooms C. Real-World Long-Term Efficacy of Chemoimmunotherapy in Advanced Stage Small-Cell Lung Cancer. Respiration. 2026:1-13. doi:10.1159/000553352
BibTeX
@article{Peeters2026,
author = {Peeters, Arne and Wauters, Els and Wauters, Isabelle and Van Hove, Karolien and Dooms, Christophe},
title = {Real-World Long-Term Efficacy of Chemoimmunotherapy in Advanced Stage Small-Cell Lung Cancer},
journal = {Respiration},
year = {2026},
pages = {1--13},
doi = {10.1159/000553352}
}
EUVIMED